Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 8, 2013Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session
The Boston Scientific (NYSE: BSX) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete...
-
Sep 17, 2013
ORBUSNEICH, BOSTON SCIENTIFIC SETTLE PATENT LITIGATION Fort Lauderdale, Fla. and Natick, Mass. (September 17, 2013) -- OrbusNeich Medical Inc. and Boston Scientific Corporation (NYSE: BSX) have...
-
Sep 17, 2013
Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX) today officially...
Sep 17, 2013REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves CourseBOSTON SCIENTIFIC REPORTS favorable SIX-MONTH RESULTS from LOTUS™ valve system clinical trial REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Natick, Mass. (Sept. 17,...
Sep 12, 2013In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE:...
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than HoursA breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years,...
Sep 4, 2013Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Stifel Nicolaus Healthcare Conference on Sept. 11 in Boston. Jeff...
- Sep 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference on Sept. 9 in New York....
Aug 21, 2013Shanghai, China (August 21, 2013) - The first patient implants of the Boston Scientific Corporation (NYSE: BSX) COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully...
Aug 21, 2013Boston Scientific Corporation (NYSE: BSX) continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA)...
-
Aug 19, 2013Innovative Bare Metal Stent Designed to Treat Peripheral Artery Disease
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial...
-
Aug 13, 2013
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the...
-
Aug 8, 2013
Boston Scientific Corporation (NYSE: BSX) announces the pricing of a public offering of $1.05 billion aggregate principal amount of its senior notes...
-
Jul 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June...
-
Jul 24, 2013
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a...
-
Jul 24, 2013Next generation intravascular ultrasound catheter improves image quality and deliverability
The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its...
-
Jul 19, 2013First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™...
-
Jul 12, 2013Device Facilitates Delivery of Interventional Devices in Complex PCI Procedures
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™...
-
Jul 11, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific...
-
Jun 26, 2013
Paris (June 26, 2013) – The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIOTM pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition...
-
Jun 25, 2013
Paris (June 25, 2013) – Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
Paris (June 24, 2013) – The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related...
-
Jun 18, 2013VANTAGE Study Interim Data Presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a...
-
Jun 17, 2013First Implant of Company's Vercise Deep Brain Stimulation Device Designed to Treat Parkinson's
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...